Table 2.
Percent change in DLQI subscale scores during TP2 (TP2 per‐protocol set)
| DLQI subscales | Baseline | Week 12 | Week 18 | Week 24 | Week 30 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pooled switched treatment group | Pooled continued treatment group | Pooled switched treatment group | Pooled continued treatment group | Pooled switched treatment group | Pooled continued treatment group | Pooled switched treatment group | Pooled continued treatment group | Pooled switched treatment group | Pooled continued treatment group | |
| Symptoms and feelings | 3.6 (1.44) | 3.6 (1.49) | −65.55 (33.289) | −66.39 (33.318) | −63.49 (35.045) | −63.99 (34.385) | −68.38 (33.851) | −66.39 (35.623) | −69.48 (32.122) | −66.83 (34.675) |
| Daily activities | 2.8 (1.68) | 2.7 (1.61) | −72.68 (35.119) | −68.43 (37.373) | −71.94 (35.829) | −71.10 (45.073) | −73.75 (39.972) | −74.04 (37.371) | −75.58 (37.279) | −72.52 (42.472) |
| Leisure | 2.5 (1.73) | 2.6 (1.70) | −69.36 (43.131) | −67.75 (40.801) | −69.32 (51.953) | −73.32 (37.275) | −72.98 (58.990) | −72.49 (45.037) | −73.53 (42.471) | −75.20 (41.905) |
| Work/school | 1.2 (1.09) | 1.2 (1.17) | −78.93 (39.895) | −67.05 (54.489) | −74.52 (44.880) | −75.89 (46.845) | −81.25 (37.892) | −75.14 (46.820) | −75.00 (50.626) | −78.31 (46.769) |
| Personal relationships | 2.0 (1.73) | 2.4 (1.84) | −71.38 (38.392) | −69.42 (42.864) | −70.52 (45.623) | −74.53 (41.282) | −76.77 (41.984) | −78.29 (38.758) | −79.18 (38.659) | −77.72 (38.889) |
| Treatment | 1.3 (0.96) | 1.4 (0.94) | −72.02 (40.115) | −77.16 (37.430) | −75.06 (38.514) | −75.73 (42.671) | −76.84 (41.035) | −78.24 (36.085) | −74.76 (39.388) | −75.39 (39.634) |
Values shown are mean (SD). Baseline refers to the start of the study before first drug administration.
Pooled switched treatment group (N = 179) included patients who switched from treatment with either GP2015 or ETN to treatment sequences ETN>GP2015 > ETN or GP2015 > ETN>GP2015 during treatment period 2, respectively.
Pooled continued treatment group (N = 267) included patients who received GP2015 or ETN continuously from treatment period 1.
DLQI, Dermatology Life Quality Index; ETN, etanercept originator product; SD, standard deviation; TP2, treatment period 2.